Assenagon Asset Management S.A. Has $10.34 Million Stock Holdings in Collegium Pharmaceutical, Inc. $COLL

Assenagon Asset Management S.A. lowered its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 38.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 312,598 shares of the specialty pharmaceutical company’s stock after selling 199,100 shares during the period. Assenagon Asset Management S.A.’s holdings in Collegium Pharmaceutical were worth $10,338,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Group One Trading LLC bought a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth about $28,000. Caitong International Asset Management Co. Ltd grew its holdings in Collegium Pharmaceutical by 205.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 427 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in Collegium Pharmaceutical in the 4th quarter valued at approximately $61,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Collegium Pharmaceutical by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 318 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after acquiring an additional 2,190 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Weiss Ratings lowered Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock opened at $36.59 on Friday. Collegium Pharmaceutical, Inc. has a twelve month low of $29.19 and a twelve month high of $50.79. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. The company’s 50-day moving average price is $34.08 and its 200-day moving average price is $39.67. The company has a market cap of $1.19 billion, a PE ratio of 17.94 and a beta of 0.74.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company had revenue of $193.52 million for the quarter, compared to the consensus estimate of $184.47 million. During the same quarter in the previous year, the business earned $1.49 earnings per share. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.